A syngeneic orthotopic EMT6 breast mouse model for preclinical immuno-oncology testing of novel anti-cancer strategies

Because of metastatic development of the disease, among other characteristics, and regardless of survival data, breast cancer was shown to be particularly difficult to treat. However, metastases as well as resistance to therapies continue to be a great challenge and the development of new therapeutic strategies is increasingly necessary.

We have fully characterized a syngeneic orthotopic EMT6 breast tumor mouse model. While immunometabolic profiling is suggestive of an immunosuppressive microenvironment, EMT6 model is only moderately responsive to immune checkpoint blockade and thus still remains offering enough range to gain improvements in combinatorial strategies, for instance. 

A syngeneic orthotopic EMT6 breast mouse model for preclinical immuno-oncology testing of novel anti-cancer strategies

Hence this model is featured of a favorable immune profile thereby making it a powerful preclinical immuno-oncology tool to be employed in investigating novel treatment combinations. 

A syngeneic orthotopic EMT6 breast mouse model for preclinical immuno-oncology testing of novel anti-cancer strategies
Contact us